Biotech Supply Chain Market Size, Share & Industry Analysis, By Offering (Software/ Platforms, Hardware and Services), By Product Type (Cell & Gene Therapies, Plasma Derived Products, Biosimilars & Biologics, Vaccines), By Supply Chain Stage (Procurement & Supplier Management, Manufacturing Supply Coordination, Packaging & Labeling), By Application (Clinical Trial Supply Chain Management, Commercial Biologics Distribution, Cold Chain), By End User (Pharmaceutical Companies & Biotechnology Companies, CDMOs & CROs, Academic & Research Institutes, and Others), and Regional Forecast, 2026-2034

The global biotech supply chain market size was valued at USD 23.50 billion in 2025. The market is projected to grow from USD 24.77 billion in 2026 to USD 46.74 billion by 2034, exhibiting a CAGR of 7.51% during the forecast period.

The global market comprises the various components used to manage the sourcing, storage, temperature-controlled packaging, transportation, traceability, and delivery of biotech products. The market is growing as biotech products are becoming more sensitive, high-value, and regulation-driven, which is encouraging companies to invest in reliable, technology-enabled, and temperature-controlled supply chain models. Rising demand for biologics, vaccines, and advanced therapies is increasing the need for specialized supply chain infrastructure as these products often require strict temperature control, validated packaging, real-time visibility, and compliant distribution. Also, the growing trend of outsourcing by biotechnology and pharmaceutical companies is encouraging clinical trial logistics providers to expand integrated clinical trial supply and commercial distribution services, making biotech supply chains more digital, specialized, and service-driven. These factors are further driving strategic collaboration and acquisitions among key companies to capitalize on the growth potential.

• For instance, in March 2025, DHL Group acquired CRYOPDP from Cryoport to strengthen its healthcare logistics capabilities. The CRYOPDP is focused on clinical trials, biopharma, and cell & gene therapy logistics, and the acquisition would enhance DHL’s specialty pharma logistics network and support its life sciences and healthcare strategy.

Furthermore, major players, such as Deutsche Post AG, United Parcel Service of America, Inc., Cencora, and FedEx Healthcare Solutions, are actively pursuing strategic collaborations and acquisitions, as well as investment initiatives to expand their offerings, enhance market access, and strengthen their market presence.

BIOTECH SUPPLY CHAIN MARKET TRENDS

Growing Shift Toward Temperature-Controlled and Specialized Biotech Logistics is a Prominent Market Trend Observed

The global market for biotech supply chain is witnessing a strong shift toward temperature-controlled and drug delivery logistics as biotech products are becoming more complex, sensitive, and high-value. Biologics, vaccines, biosimilars, plasma-derived products, and cell & gene therapies often require strict temperature ranges, validated packaging, real-time shipment monitoring, and faster delivery timelines. As a result, companies are moving away from general logistics models and investing in specialized cold chain management, cryogenic storage, multi-temperature warehouses, and compliant transportation systems. This trend is becoming significant as any temperature deviation or shipment delay can affect product quality, patient safety, and regulatory compliance, encouraging biotech companies and logistics providers to build more reliable and controlled supply chain models.

• In January 2025, UPS acquired Frigo-Trans and BPL to strengthen its healthcare cold-chain logistics capabilities across Europe. The development would support customers needing temperature-controlled and time-critical logistics.

MARKET DYNAMICS

MARKET DRIVERS

Download Free sample to learn more about this report.

Rising Demand for Biologics and Vaccines to Drive Need for Specialized Cold Chain Supply Networks

The global biotech supply chain market growth is driven by the increasing demand for biologics, vaccines, biosimilars, and advanced therapies. These therapies require more controlled, reliable, and compliant supply chain models. They are highly sensitive to temperature changes and handling delays, so companies need validated cold storage, real-time monitoring, specialized packaging, and temperature-controlled transportation to protect product quality from manufacturing to final delivery. As more biotech products move into clinical trials and commercial distribution, the risk of product loss, regulatory non-compliance, and patient access delays also increases. This is encouraging pharmaceutical companies, biotech firms, and logistics providers to invest in stronger cold chain networks, making specialized bio-tech supply chain services a key market growth driver.

• In April 2025, DHL Group announced an investment of USD 2.26 billion by 2030 in DHL Health Logistics to strengthen infrastructure and technology across storage, order fulfillment, distribution, global shipping, and last-mile delivery. The investment would help create more resilient and scalable supply chains for life sciences and healthcare customers.

MARKET RESTRAINTS

High Cost of Cold Chain and Cryogenic Infrastructure to Limit Market Expansion

The market faces a significant growth restraint due to the high cost of building and maintaining cold chain and cryogenic infrastructure. Biologics, vaccines, biosimilars, and cell & gene therapies require validated storage systems, ultra-low temperature freezers, cryogenic containers, specialized packaging, calibrated monitoring devices, and trained quality teams. These requirements increase capital investment and operating costs for logistics providers, CROs, CDMOs, and biotech companies. As a result, smaller biotech firms and emerging-market suppliers find it difficult to adopt advanced cold chain systems at scale. This can slow market growth as the supply chain becomes more expensive, harder to expand, and more exposed to product-loss risk when the temperature-controlled infrastructure is not strong enough.

• In December 2021, Sandoz issued a nationwide recall of one lot of Enoxaparin Sodium Injection due to a temperature excursion during shipping. Such instances show how failures in temperature-controlled distribution can lead to product recalls, financial loss, and additional compliance pressure, which highlights the cost and operational burden of maintaining reliable cold chain infrastructure.

MARKET OPPORTUNITIES

Expansion of Cell and Gene Therapy Commercialization to Create Opportunities for Cryogenic Supply Chain Providers

The market is anticipated to experience growth from the rising commercialization of cell and gene therapies. These products require highly specialized logistics support from collection to final patient delivery. Unlike conventional biologics, many cell and gene therapies need cryogenic storage, ultra-low temperature transport, chain-of-identity tracking, chain-of-custody documentation, and tightly coordinated delivery timelines. As more therapies move from clinical trials to commercial use, biotech companies will need supply chain partners that can protect product integrity, reduce handling risk, and support global treatment center networks. This creates a strong growth opportunity for cryogenic logistics providers, specialized packaging companies, temperature-monitoring solution providers, and digital traceability platforms, as advanced therapy supply chains become more complex and patient-specific.

• In October 2025, Cryoport announced that Cryoport Systems achieved ISO 21973:2020 certification for the transportation of human cells for therapeutic use. The certification supports transport safety, traceability, and integrity standards for cell and gene therapies, highlighting the rising opportunity for specialized cryogenic supply chain providers in advanced therapy logistics.

MARKET CHALLENGES

Managing Temperature Excursions and Product Loss Remains a Key Market Challenge

The market faces a major challenge in maintaining product quality across long and complex supply routes. Biologics, vaccines, plasma-derived products, biosimilars, and advanced therapies are highly sensitive to temperature changes, so even a short excursion during storage or transportation can affect product stability, create compliance risk, and lead to shipment rejection or recall. These factors make supply chain operations more difficult as companies must invest in validated packaging, continuous temperature monitoring, trained handling teams, and strong contingency planning. As a result, the cost and operational burden of biotech distribution increases, while any failure can directly affect patient access, company reputation, and overall market confidence.

• In July 2025, GSK’s Benlysta was recalled under an FDA enforcement report due to CGMP deviations, with the recall reason including potential temperature excursions caused by transit delays. The instance showcased how even established biopharma supply chains remain exposed to shipment delays and temperature-control failures, which can result in recalls and additional compliance pressure.

Segmentation Analysis

By Offering

Services Segment Dominated Due to Rising Outsourcing of Specialized Biotech Supply Chain Operations

Based on the offering, the market is categorized into software/platforms, hardware, and services.

The services segment dominated the global biotech supply chain market share in 2025. The high share was allocated to the segment as biotech supply chains require continuous operational support across clinical trial supply, cold chain logistics, warehousing, packaging, labeling, distribution, and compliance management. Many pharmaceutical and biotechnology companies do not maintain a complete in-house logistics infrastructure for every region, temperature condition, and product category. As a result, they increasingly depend on specialized third-party service providers that can manage validated facilities, GDP-compliant transportation, real-time shipment visibility, and regulated product handling. This makes services the largest offering segment as recurring logistics, storage, and distribution activities generate higher market value than one-time hardware or software purchases.

• In February 2024, DHL Supply Chain announced a USD 200 million investment to expand its life sciences and healthcare logistics capabilities in the Americas. The investment would expand its dedicated warehouse footprint, add new facilities, and strengthen temperature-controlled logistics solutions for life sciences customers.

The software/platforms segment is expected to grow at a CAGR of 10.72% over the forecast period.

To know how our report can help streamline your business, Speak to Analyst

By Product Type

Biosimilars & Biologics Segment Led Due to High Commercial Volumes and Strict Handling Needs

Based on product type, the market is segmented into cell & gene therapies, plasma derived products, biosimilars & biologics, vaccines, and others.

In 2025, the biosimilars & biologics segment captured the highest share by product type as these products are already widely commercialized across immunology, oncology, diabetes, neurology, and rare disease treatment areas. Compared with cell and gene therapies, biologics and biosimilars have broader patient coverage, larger commercial supply volumes, and more established global distribution channels. At the same time, these products require controlled storage, validated shipping, reliable biotechnology inventory management, and quality documentation to protect product stability. This creates a great and recurring demand for biotech manufacturing solutions, making biosimilars and biologics the leading product type segment.

• In June 2025, UCB announced major investment in a new U.S. biologics manufacturing facility and stated that it is also scaling up U.S.-based CMO partnerships to support its growth drivers. The development would support a more resilient supply chain and help global manufacturing capacity keep pace with its innovation pipeline.

The cell & gene therapies segment is projected to grow at a CAGR of 14.45% during the forecast period.

By Supply Chain Stage

Transportation & Distribution Segment Dominated as Biotech Products Require Controlled and Reliable Delivery Networks

Based on the supply chain stage, the market is segmented into procurement & supplier management, manufacturing supply coordination, packaging & labeling, warehousing & inventory management, transportation & distribution, and others.

The transportation & distribution segment held a dominant position in the market in 2025. Moving biotech products from manufacturers to depots, clinical sites, hospitals, pharmacies, and treatment centers is one of the most critical and frequently used parts of the supply chain. Biotech products often need refrigerated, frozen, ultra-low, or cryogenic conditions during movement, and any delay or temperature deviation can affect product quality. As more specialty medicines and biologics reach the market, companies need stronger national and cross-border distribution networks with automation, cold storage, and route reliability. This makes transportation and distribution a dominant stage as it directly connects product availability with patient access.

• In November 2025, Cencora announced a USD 1.00 billion investment through 2030 to strengthen its U.S. pharmaceutical distribution network. The investment would include a second national distribution center, expanded facilities in Alabama and California, advanced automation, and major increases in refrigerated and frozen storage capacity to support specialty medicines.

The manufacturing supply coordination segment is projected to grow at a CAGR of 8.67% during the forecast period.

By Application

Cold Chain & Temperature-Controlled Logistics Segment Led Due to Rising Demand for Product Integrity and Compliance  

Based on the application, the market is segmented into clinical trial supply chain management, commercial biologics distribution, cold chain & temperature-controlled logistics, API, raw material & consumables supply management, serialization, traceability & compliance, and others.

The cold chain & temperature-controlled logistics segment dominated the market in 2025 by application. As product portfolios become more complex, the need for temperature-controlled infrastructure increases across clinical trials and commercial distribution. This makes cold chain logistics the leading application area as it directly supports product safety, regulatory compliance, and uninterrupted treatment delivery.

• In October 2025, World Courier announced the expansion of its global cryogenic network for cell and gene therapy logistics. The company added new cryogenic facilities in São Paulo and Beijing as part of its plan to equip all 22 depots with cryogenic capability. Further, supporting compliant storage, transport, and chain-of-custody needs for advanced therapies and biologics.   

The clinical trial supply chain management segment is projected to grow at a CAGR of 10.14% over the global biotech supply chain market forecast period.

By End User

Pharmaceutical Companies & Biotechnology Companies Segment Dominated Due to Supervised Administration of Advanced Therapies

Based on end user, the market is segmented into pharmaceutical companies & biotechnology companies, CDMOs & CROs, academic & research institutes, and others.

In 2025, the pharmaceutical companies & biotechnology companies segment dominated the market by end user. These companies are the primary developers, manufacturers, and commercial owners of biologics, biosimilars, vaccines, and advanced therapies. They carry direct responsibility for product quality, regulatory compliance, launch readiness, and patient access, which makes supply chain reliability a strategic priority. As pipelines expand and products enter more countries, these companies need specialized partners for clinical supply, commercial distribution, cold chain storage, serialization, and quality management. This makes pharma and biotech companies the leading end-user segment as they generate the highest demand for integrated and compliant biotech supply chain solutions.

• In December 2025, Cencora announced investments to enhance its global pharmaceutical logistics services and cold chain capabilities in Europe and the U.S. The pharmaceutical companies increasingly seek partners that can provide comprehensive support across multiple markets, including storage, distribution, serialization, quality assurance, refrigerated, frozen, ultra-low, and cryogenic logistics.

The CDMOs & CROs segment is projected to grow at a CAGR of 8.53% over the forecast period.

Biotech Supply Chain Market Regional Outlook

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America held the dominant share in 2024 at USD 10.97 billion and maintained its leading position in 2025 at USD 11.52 billion. The market in the region is growing due to strong biologics, vaccines, and cell & gene therapy activity. High clinical trial volume and strong specialty pharma distribution networks are increasing demand for cold chain logistics, serialization, and real-time supply chain visibility.

U.S. Biotech Supply Chain Market

Given North America's substantial contribution and the U.S. dominance in the region, the U.S. market is estimated at around USD 11.48 billion in 2026, accounting for roughly 43.85% of the global market.

Europe

Europe is projected to grow at 6.62% over the coming years, the second-highest among all regions, and reach a valuation of USD 6.38 billion by 2026. Growth in European countries is supported by strict regulatory compliance, strong biologics manufacturing, and rising biosimilar adoption across major markets such as Germany, France, the U.K., Italy, and Spain. This is increasing the need for validated storage, GDP-compliant transportation, and cross-border biotech distribution services.

U.K. Biotech Supply Chain Market

The U.K. market is estimated at USD 1.21 billion in 2026, accounting for roughly 4.62% of the global market.

Germany Biotech Supply Chain Market

Germany's market is projected to reach approximately USD 1.36 billion in 2026, equivalent to around 5.19% of the global market.

Asia Pacific

The Asia Pacific market is estimated to reach USD 6.07 billion in 2026, securing third place globally. The region is expanding in biologics manufacturing, clinical trials, and vaccine distribution capacity. Lower manufacturing costs and rising biotech investments are creating demand for cold chain networks, clinical trial supply services, and temperature monitoring platforms.

Japan Biotech Supply Chain Market

The Japanese market size in 2026 is estimated at around USD 2.01 billion, accounting for approximately 7.68% of the global market.

China Biotech Supply Chain Market

China's market is projected to be among the largest worldwide, with 2026 revenues estimated at around USD 1.24 billion, accounting for approximately 4.75% of global sales.

India Biotech Supply Chain Market

The Indian market is estimated at around USD 0.67 billion in 2026, accounting for roughly 2.55% of global revenue.

Latin America and the Middle East & Africa

Latin America and the Middle East & Africa regions are expected to witness growth in this market during the forecast period. The market in Latin America is estimated to reach a valuation of USD 0.69 billion in 2026. The growth in the region is driven by improving healthcare access, rising vaccine and biologics demand, and expanding clinical trial activity. In the Middle East & Africa, the GCC market is set to reach USD 0.47 billion in 2026.

South Africa Biotech Supply Chain Market

The South African market is projected to reach approximately USD 0.15 billion by 2026, accounting for roughly 0.56% of global revenue.

COMPETITIVE LANDSCAPE

Key Industry Players

Innovative Product Launches among Key Companies to Propel Market Progress

The global biotech supply chain market is characterized by the presence of large logistics providers, specialty pharmaceutical distributors, clinical trial supply companies, cold chain packaging providers, and digital supply chain platform vendors. Key companies are focusing on strengthening temperature-controlled logistics, expanding healthcare warehousing capacity, improving clinical trial supply services, and adopting serialization and track-and-trace platforms to support the movement of complex biotech products. The market is also witnessing growing investment in cryogenic logistics, real-time monitoring, chain-of-custody platforms, and advanced therapy supply networks as biologics, biosimilars, vaccines, and cell & gene therapies continue to expand globally. These factors are encouraging key players to direct their resources towards new product launches, and strategic collaborations to cater to the rising market demand.

• For instance, in April 2026, Thermo Fisher Scientific Inc. launched a next-generation, integrated cell line development platform that enables biologics developers to accelerate time to clinic while maintaining regulatory confidence and commercial scalability.

Major players such as Deutsche Post AG, UPS Healthcare, Cencora, and FedEx, are some of the key players actively competing through service expansion, acquisitions, technology integration, and strategic partnerships. Companies with strong global infrastructure, validated cold chain facilities, regulatory expertise, and end-to-end distribution capabilities are expected to maintain a leading position in the market. Additionally, rising demand for patient-specific therapies and temperature-sensitive biologics is encouraging key players to develop specialized logistics models that improve product safety, reduce supply disruptions, and strengthen compliance across global biotech supply chains.

LIST OF KEY BIOTECH SUPPLY CHAIN COMPANIES PROFILED

• Deutsche Post AG (Germany)
• United Parcel Service of America, Inc. (U.S.)
• Cencora, inc (U.S.)
• FedEx Healthcare Solutions (U.S.)
• Kuehne+Nagel (Switzerland)
• McKesson Corporation (U.S.)
• Cardinal Health (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Catalent, Inc (U.S.)
• P. Moller - Maersk (Denmark)

KEY INDUSTRY DEVELOPMENTS

• February 2026: Cryoport, Inc., a leading provider of temperature-controlled supply chain solutions for the life sciences, launched the MVE Fusion 800 Series, a line of MVE Biological Solutions Fusion technology. The self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN₂) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designed for space-constrained environments.
• November 2025: UPS completed the acquisition of Andlauer Healthcare Group, a North American healthcare supply chain company offering customized third-party logistics and specialized cold chain transportation solutions.
• October 2025: Cryoport Systems expanded its global footprint with a new 55,000-square-foot Global Supply Chain Center in Paris, France, designed to support complex life sciences supply chain needs, including biologistics and bioservices.
• September 2025: DHL agreed to acquire SDS Rx, a U.S.-based healthcare final-mile delivery provider operating from more than 200 locations. DHL stated that the acquisition would expand its life sciences and healthcare capabilities across time-critical logistics.
• January 2025: Cryoport unveiled the Cryoport Express Cryogenic HV3 Shipping System, a high-volume cryogenic shipping system for biologics and other temperature-sensitive therapies.

REPORT COVERAGE

The report provides a detailed global biotech supply chain market analysis. It focuses on key aspects, including major offerings, software platforms, hardware systems, supply chain services, product types, supply chain stages, applications, and end users. It also offers insights into the growing adoption of cold chain logistics, temperature monitoring platforms, serialization and track-and-trace systems, cryogenic shipping solutions, and clinical trial supply management services for biotech products. In addition, the report covers the impact of rising biologics demand, expanding cell and gene therapy commercialization, increasing clinical trial activity, regulatory compliance needs, and strategic initiatives by key market players. The report further evaluates market trends, drivers, restraints, opportunities, and the competitive landscape across major regions. It also highlights key industry developments, supply chain investments, technology adoption, partnerships, acquisitions, and company strategies that are expected to shape the growth of the global market during the forecast period.

Request for Customization   to gain extensive market insights.

Report Scope & Segmentation